European Archives - Page 1461 of 1599 - European Medical Journal

Merck Welcomes ZEISS and Hamilton Thorne as New Members of the Global Fertility Alliance

Darmstadt, Germany, June 30, 2016 – Merck, a leading science and technology company, today announced together with Illumina Inc., San Diego, US, and…

Introducing EMJ Nephrology 4.1

United Kingdom, July 5, 2016: Welcome to the 2016 edition of EMJ Nephrology, which provides extensive coverage of research and developments across the…

Best Award Winners at ERA-EDTA 2016

The ERA-EDTA recognised a selection of authors for what the organisation deemed to be the best presentations of research abstracts at the congress.

Anti-Interleukin-1 Alpha Antibody MABp1 Improves Outcomes Significantly over Placebo

Barcelona-Lugano, July 02, 2016 – A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and…

EMJ Nephrology 4.1 2016

Welcome to the 2016 edition of EMJ Nephrology, which provides extensive coverage of research and developments across the field of nephrology.

Review of the 53rd European Renal Association - European Dialysis and Transplant Association Congress 2016

This year’s congress stood on the shoulders of the giants of medical history; from Semmelweis and his famous improvements to hygiene in hospitals, to…

Protecting Heart, Vessels, and Bone: New Ways to Control Phosphorus

Prof Alexander Rosenkranz and Prof Markus Ketteler welcomed the audience and the expert panel of the symposium, and briefly described the programme of…

New Insights into Iron Metabolism and Deficiency

The symposium provided an overview of the prevalence of iron deficiency and the associated disease burden in patients with chronic kidney disease (CKD).

Secondary Carnitine Deficiency in Dialysis Patients: Shall We Supplement It?

Carnitine, essential for fatty acid β-oxidation, is obtained from diet and through de novo biosynthesis.

Editor’s Pick: Targeted Agents in Patients with Metastatic Renal Cell Carcinoma on Dialysis: Myths and Reality

Agents targeting the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathway, as well as mammalian target of rapamycin (mTOR) inhibitors…